Most Popular Stories
- Healthcare jobs will grow the fastest of all industries
- Hospitals lose reimbursement for 'unnecessary' ER visits
- Online tools, social media ease clinical recruiting, research
- Measuring ROI key to EHR success, adoption
- eHealth Initiative issues IT recommendations for ACOs
- Patient satisfaction equal for physician, hospitalist care
Featured Jobs
-
Electronic Health Records Application Support Manager RN-New Year New Career
Avanti on behalf of Respected Health System - San Francisco, CA -
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA -
Epic Ambulatory Beacon Consultant
Meditology Services - NC
Events
- CIO Healthcare Summit
March 11-14 — Scottsdale, AZ - IHI's Transforming the Primary Care Practice
May 1-3, 2012 — San Diego, CA - Medicare Risk Adjusted Revenue and Plan Payments
April 12 - 13, 2012 — Baltimore, MD - 3rd Healthcare IT Innovation Asia
Mar 14-15 2012 — Singapore
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
SPOTLIGHT: Avandia critic an industry watchdog
June 4, 2007 — 7:01pm ET
So what's the story with Dr. Steven Nissen? The cardiologist who chairs the Cleveland Clinic's department of cardiovascular medicine made international headlines when he released a study suggesting that blockbuster diabetes drug Avandia posed greater heart health risks than expected. But this isn't the first time that Nissen has had a major impact on the drug industry. For years, Nissen has been an influential watchdog, respected by legislators on Capitol Hill and feared by pharmas. Article
SHARE WITH:
Related Stories
- Glaxo: Avandia critic should pay for stock drop
- ALSO NOTED: Cleveland Clinic ousts cardiologist; The return of the school nurse; and much more...
- Antibody-coated stent lands in North American market
- Topol to leave Cleveland Clinic
- Cleveland Clinic to investigate conflict of interest charges
- Cleveland Clinic announces landmark painkiller study
- Topol's demotion raises issues
- J&J Natrecor marketing investigated
- Cleveland Clinic training providers in Saudi Arabia
- Cleveland Clinic, healthcare employers to hire more outpatient staff in 2012
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
